{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:54:18Z","timestamp":1781754858081,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01790-2","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:49:35Z","timestamp":1780663775000},"page":"3315-3329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Bimekizumab\u2019s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-2894","authenticated-orcid":false,"given":"Steven","family":"Daveluy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice Bendix","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-7001","authenticated-orcid":false,"given":"Hadar","family":"Lev-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek Cezary","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-3674","authenticated-orcid":false,"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-4385","authenticated-orcid":false,"given":"Martina Lee","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-2493","authenticated-orcid":false,"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-1492","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4397-6329","authenticated-orcid":false,"given":"Nicola","family":"Tilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0217-6313","authenticated-orcid":false,"given":"Bartosz","family":"Lukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-9607","authenticated-orcid":false,"given":"Linnea","family":"Thorlacius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"12","key":"1790_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","volume":"21","author":"ZS Patel","year":"2017","unstructured":"Patel ZS, Hoffman LK, Buse DC, et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21(12):49.","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"1790_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000496234","volume":"5","author":"L Thorlacius","year":"2019","unstructured":"Thorlacius L, Esmann S, Miller I, et al. Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument. Skin Appendage Disorders. 2019;5(4):221\u20139.","journal-title":"Skin Appendage Disorders"},{"issue":"1","key":"1790_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","volume":"138","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Cohen AD, Gislason GH, et al. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52\u20137.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1790_CR4","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"\u0141 Matusiak","year":"2020","unstructured":"Matusiak \u0141. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1790_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","volume":"188","author":"LAV Orenstein","year":"2023","unstructured":"Orenstein LAV, Salame N, Siira MR, et al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;188(1):41\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1790_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2340\/00015555-1082","volume":"91","author":"S Esmann","year":"2011","unstructured":"Esmann S, Jemec GBE. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328\u201332.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1790_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2340\/00015555-2967","volume":"98","author":"K Kaaz","year":"2018","unstructured":"Kaaz K, Szepietowski JC, Matusiak \u0141. Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(8):757\u201361.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1790_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434\u201342.","journal-title":"Br J Dermatol"},{"issue":"10443","key":"1790_CR9","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"key":"1790_CR10","doi-asserted-by":"crossref","unstructured":"Shi VY, Ingram JR, Lev-Tov H, et al. Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week results from BE HEARD I&II. Dermatol Ther (Heidelb). 2025;2553\u201370.","DOI":"10.1007\/s13555-025-01465-4"},{"issue":"11","key":"1790_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: A phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1790_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamadermatol.2023.0797","volume":"159","author":"A Garg","year":"2023","unstructured":"Garg A, Zema C, Ciaravino V, et al. Validation of the hidradenitis suppurativa investigator global assessment: A novel hidradenitis suppurativa-specific investigator global asessment for use in interventional trials. JAMA Dermatol. 2023;159(6):606\u201312.","journal-title":"JAMA Dermatol"},{"key":"1790_CR13","volume-title":"Association between increasingly stringent clinical responses and improvements in pain, HRQoL, and work productivity in patients with hidradenitis suppurativa: 1-year phase 3 results from BE HEARD Iⅈ PCR53","author":"B Horv\u00e1th","year":"2024","unstructured":"Horv\u00e1th B, M\u00f8rup MF, Davis L, et al. Association between increasingly stringent clinical responses and improvements in pain, HRQoL, and work productivity in patients with hidradenitis suppurativa: 1-year phase 3 results from BE HEARD Iⅈ PCR53. ISPOR Europe 2024. Barcelona, Spain, 2024."},{"issue":"1","key":"1790_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/bjd\/ljaf067","volume":"193","author":"JS Kirby","year":"2025","unstructured":"Kirby JS, Thorlacius L, Lambert J, et al. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL\u00a9) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. Br J Dermatol. 2025;193(1):93\u2013104.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1790_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, Thorlacius L, Villumsen B, et al. The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183(2):340\u20138.","journal-title":"Br J Dermatol"},{"issue":"86","key":"1790_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19860","volume":"19","author":"K Pickett","year":"2015","unstructured":"Pickett K, Loveman E, Kalita N, et al. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015;19(86):1\u2013176.","journal-title":"Health Technol Assess"},{"issue":"9","key":"1790_CR17","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s11136-020-02499-1","volume":"29","author":"AW Vilsb\u00f8ll","year":"2020","unstructured":"Vilsb\u00f8ll AW, Kragh N, Hahn-Pedersen J, et al. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study. Qual Life Res. 2020;29(9):2529\u201339.","journal-title":"Qual Life Res"},{"issue":"4","key":"1790_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1790_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/bjd\/ljad069","volume":"188","author":"A Garg","year":"2023","unstructured":"Garg A, Rawal S, Akilov O, et al. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project. Br J Dermatol. 2023;188(6):808\u201310.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1790_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjd.21798","volume":"187","author":"B Midgette","year":"2022","unstructured":"Midgette B, Strunk A, Akilov O, et al. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. Br J Dermatol. 2022;187(6):927\u201335.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1790_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/bjd\/ljad491","volume":"190","author":"L Thorlacius","year":"2024","unstructured":"Thorlacius L, Riis PT, Musaeus KD, et al. Severity rating of specific skin lesions in hidradenitis suppurativa: the patient perspective. Br J Dermatol. 2024;190(4):579\u201381.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1790_CR22","first-page":"859","volume":"50","author":"CS Carlin","year":"2004","unstructured":"Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1790_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15285","volume":"35","author":"B Sigurgeirsson","year":"2022","unstructured":"Sigurgeirsson B, Browning J, Tyring S, et al. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial. Dermatol Ther. 2022;35(3):e15285.","journal-title":"Dermatol Ther"},{"issue":"10","key":"1790_CR24","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, et al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb). 2024;14(10):2841\u201357.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1790_CR25","unstructured":"McLeod L, Mallya UG, Fox T, et al. Psoriasis patients with PASI 90 response achieve greater health-related quality of life improvements than those with PASI 75\u201389 response. Winter Clinical Dermatology Conference. Maui, Hawaii, 2015."},{"issue":"10476","key":"1790_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338.","journal-title":"Lancet"},{"issue":"4","key":"1790_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.214","volume":"3","author":"AP Kaur","year":"2023","unstructured":"Kaur AP, Laing ME, Griffin L, et al. Quality of life in hidradenitis suppurativa (acne inversa): A scoping review. Skin Health Dis. 2023;3(4):e214.","journal-title":"Skin Health Dis"},{"issue":"10","key":"1790_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2340\/00015555-3012","volume":"98","author":"AB Kimball","year":"2018","unstructured":"Kimball AB, Tzellos T, Calimlim BM, et al. Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: post hoc analysis of pooled data from PIONEER I and II. Acta Derm Venereol. 2018;98(10):932\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1790_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1790_CR30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13555-025-01343-z","volume":"15","author":"C Sayed","year":"2025","unstructured":"Sayed C, Porter M, Hamzavi I, et al. Bimekizumab 2-year impact on HS symptoms by baseline draining tunnel count: data from BE HEARD EXT. Dermatol Ther (Heidelb). 2025;15(3):483\u2013562.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1790_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/bjd\/ljae442","volume":"192","author":"J Rastrick","year":"2025","unstructured":"Rastrick J, Edwards H, Ferecsk\u00f3 AS, et al. The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. Br J Dermatol. 2025;192(4):660\u201371.","journal-title":"Br J Dermatol"},{"issue":"16-17","key":"1790_CR32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/1750743X.2024.2401308","volume":"16","author":"RB Shams","year":"2024","unstructured":"Shams RB, Sayed CJ. Bimekizumab for the treatment of hidradenitis suppurativa. Immunotherapy. 2024;16(16\u201317):1005\u201313.","journal-title":"Immunotherapy"},{"issue":"2","key":"1790_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01790-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:24:21Z","timestamp":1781753061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01790-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01790-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All details of authors\u2019 affiliation or involvement in an organisation or entity with a financial or non-financial interest in the subject matter or materials discussed in this manuscript are disclosed. Steven Daveluy: Speaker for AbbVie, Novartis and UCB; consultant for AbbVie, Novartis and UCB; research grants from AbbVie, Incyte, Insmed, MoonLake Immunotherapeutics, Pfizer, Regeneron, Sanofi and UCB. Steven Daveluy is an Editorial Board member of\n                      Dermatology and Therapy\n                      but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Alice Bendix Gottlieb: Received research\/educational grants from Bristol Myers Squibb, Janssen, MoonLake Immunotherapeutics and UCB (all paid to Mount Sinai School of Medicine until 1\u00a0May\u00a02025); Sub I on studies at UTSW from Bristol Myers Squibb and Janssen; received honoraria as an advisory board member and consultant for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Oruka, Sanofi, SunPharma, Takeda, Teva and UCB. Matthias Augustin: Consultant, lecturer or researcher, and\/or has received research grants from companies manufacturing drugs for psoriasis, including AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Eli Lilly and Company, Galderma, Hexal, Incyte, Janssen, Klinge, LEO Pharma, Medac, MSD, Mylan B.V., Novartis, Pfizer, Sandoz, Sun Pharma, Takeda, UCB and Viatris. Hadar Lev-Tov: Consultant for Novartis and UCB. Jacek Cezary Szepietowski: Consultant and advisory board member of AbbVie, Almirall, Boehringer Ingelheim, Galderma, LEO Pharma, Novartis, Pierre Fabre, Sandoz, Sanofi-Genzyme and UCB; speaker for AbbVie, Almirall, Boehringer Ingelheim, Janssen, Eli Lilly and Company, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi Genzyme and UCB; investigator for AbbVie, Acelyrin, Almirall Hermal, Amgen, AnaptysBio, Argenx, Aslan, Boehringer Ingelheim, Biocom, Bio Thera, Bristol Myers Squibb, Celltrion, CuraTeQ Biologics, DICE Therapeutics, Eli Lilly and Company, Helm AG, Galapagos, Galderma, Janssen, Incyte, InflaRx, Kiniksa, Kymab Limited, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, MoonLake Immunotherapeutics, Novartis, Pierre Fabre, Pfizer, Regeneron Pharmaceuticals, Takeda, Teva, Trevi Therapeutics, UCB, Uni Therapeutics and Ventyx Bioscience. Jacek Cezary Szepietowski is an Editorial Board member of\n                      Dermatology and Therapy\n                      but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Barbara Horv\u00e1th: Received fees for educational grants and investigator-initiated studies from AbbVie and Janssen-Cilag; received fees for investigator-initiated studies from Akari Therapeutics, Celgene, Novartis and Solenne B.V.; advisory board member for AbbVie, Janssen-Cilag, Novartis and UCB; consultant for AbbVie, Akari Therapeutics, Celgene, Janssen-Cilag, LEO Pharma, Novartis, Philips, Regeneron, Roche, Sanofi and UCB; all contracts reviewed and signed by the Board of Directors with fees paid to the institution. Martina Lee Porter: Consultant and investigator for AbbVie, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Eli Lilly and Company, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, UCB, Ventyx and Zura Bio; consultant for Almirall, FIDE, Insmed, Oruka, Otsuka, Propeller Biosciences, Spyre and Trifecta Clinical\/WCG; investigator for AnaptysBio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals and Regeneron; received royalties from Beth Israel Deaconess Medical Center; received fellowship funding to institution from AbbVie. Koremasa Hayama: Principal investigator for and consultancy\/advisory boards for AbbVie, Boehringer Ingelheim, Novartis, Sanofi and UCB; speaker fees\/grants from AbbVie, Boehringer Ingelheim, Eisai, Maruho, Novartis and UCB. J\u00e9r\u00e9my Lambert, Nicola Tilt, Bartosz Lukowski: Employees and shareholders of UCB. Linnea Thorlacius: Co-copyright holder of HIDE\n                      \u00a9\n                      (HIdradenitis suppurativa DrainagE), HiSQOL\n                      \u00a9\n                      (Hidradenitis Suppurativa Quality of Life) and HS-IGA\n                      \u00a9\n                      (Hidradenitis Suppurativa Investigator Global Assessment).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Ethics approval was obtained from the relevant institutional review boards at participating sites. BE HEARD I&II have previously been published and full ethical approval was acquired for both studies. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}